Geode Capital Management LLC Has $32.54 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Geode Capital Management LLC lifted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 9.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,448,040 shares of the company’s stock after buying an additional 126,306 shares during the quarter. Geode Capital Management LLC’s holdings in Nurix Therapeutics were worth $32,544,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Renaissance Technologies LLC lifted its position in Nurix Therapeutics by 80.7% during the 2nd quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock worth $6,762,000 after acquiring an additional 144,700 shares during the last quarter. TD Asset Management Inc bought a new stake in Nurix Therapeutics during the 2nd quarter valued at approximately $593,000. Candriam S.C.A. grew its holdings in Nurix Therapeutics by 30.5% in the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after buying an additional 272,136 shares during the last quarter. Bank of New York Mellon Corp increased its position in Nurix Therapeutics by 31.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 209,136 shares of the company’s stock worth $4,365,000 after buying an additional 49,918 shares during the period. Finally, FMR LLC lifted its holdings in shares of Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after buying an additional 511,256 shares during the last quarter.

Analyst Upgrades and Downgrades

NRIX has been the subject of several research analyst reports. BTIG Research started coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $35.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price target on shares of Nurix Therapeutics in a report on Tuesday, December 10th. UBS Group assumed coverage on shares of Nurix Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $35.00 price objective for the company. Robert W. Baird assumed coverage on shares of Nurix Therapeutics in a research note on Friday, September 6th. They issued an “outperform” rating and a $26.00 target price on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price target for the company. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.35.

Nurix Therapeutics Trading Down 2.1 %

NRIX opened at $19.57 on Thursday. The firm has a 50-day moving average price of $23.13 and a two-hundred day moving average price of $22.40. Nurix Therapeutics, Inc. has a 1-year low of $7.65 and a 1-year high of $29.56. The stock has a market capitalization of $1.39 billion, a PE ratio of -6.73 and a beta of 2.12.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, research analysts predict that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Christine Ring sold 3,290 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the transaction, the insider now owns 24,592 shares of the company’s stock, valued at approximately $614,800. This represents a 11.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,368 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares of the company’s stock, valued at $905,661. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 18,401 shares of company stock valued at $437,453. 9.80% of the stock is currently owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.